Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) – Equities researchers at HC Wainwright issued their FY2028 earnings estimates for Coherus BioSciences in a research note issued to investors on Monday, September 16th. HC Wainwright analyst D. Tsao expects that the biotechnology company will earn $0.08 per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Coherus BioSciences’ current full-year earnings is ($1.07) per share.
Coherus BioSciences (NASDAQ:CHRS – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The company had revenue of $64.98 million during the quarter, compared to the consensus estimate of $57.08 million.
Check Out Our Latest Report on Coherus BioSciences
Coherus BioSciences Stock Up 1.0 %
CHRS opened at $1.05 on Thursday. The business’s fifty day simple moving average is $1.42 and its 200 day simple moving average is $1.81. Coherus BioSciences has a 52 week low of $1.01 and a 52 week high of $4.73. The stock has a market cap of $120.46 million, a PE ratio of -1.35 and a beta of 0.66.
Institutional Trading of Coherus BioSciences
A number of hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its stake in Coherus BioSciences by 694.2% during the first quarter. BNP Paribas Financial Markets now owns 346,157 shares of the biotechnology company’s stock worth $827,000 after acquiring an additional 302,570 shares in the last quarter. Nomura Holdings Inc. lifted its holdings in shares of Coherus BioSciences by 225.1% during the fourth quarter. Nomura Holdings Inc. now owns 68,300 shares of the biotechnology company’s stock valued at $227,000 after purchasing an additional 47,290 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Coherus BioSciences in the 1st quarter worth approximately $94,000. Birchview Capital LP purchased a new stake in shares of Coherus BioSciences in the 4th quarter worth approximately $366,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Coherus BioSciences during the 1st quarter valued at approximately $108,000. 72.82% of the stock is owned by hedge funds and other institutional investors.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
See Also
- Five stocks we like better than Coherus BioSciences
- ETF Screener: Uses and Step-by-Step Guide
- Viking Therapeutics Is Having a Year to Remember: Time to Buy?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Leverage Proven Stock Factors With These Top 3 Smart Beta ETFs
- Why Are These Companies Considered Blue Chips?
- Spread Your Bets: Winning the AI Race With Energy ETFs
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.